Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co., Inc.

http://www.merck.com

Latest From Merck & Co., Inc.

Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin

At ESMO, data showed objective response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.

Clinical Trials Research & Development

Back to The Past: The Case for Improving Upon, Not Throwing Out Traditional Cancer Phase I Study Designs

US FDA has pushed sponsors away from the traditional dose-finding designs for cancer drugs in recent years. But academics continue to make a case for keeping the 3+3 design with some improvements.

Clinical Trials ImmunoOncology

ESMO: Regeneron Mounts Credible Challenge To Keytruda With Libtayo Survival Data In NSCLC

Libtayo looks to have surpassed all competitors but Merck’s Keytruda in first line NSCLC, but the unique ‘all-comers’ trial design of EMPOWER-Lung-3 complicates the picture.

Commercial Companies

From China With Discount? BeiGene Moves Towards First Global PD-1 Green Light

Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.

China ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abmaxis
    • Acacia Biosciences
    • Afferent Pharmaceuticals
    • ArQule, Inc.
    • Avecia Biologics Limited
    • Banyu Pharmaceutical Co., Ltd.
    • Calporta Therapeutics
    • cCAM Biotherapeutics Ltd.
    • Cubist Pharmaceuticals, Inc. (Adolor Corporation (ADLR)
    • Calixa Therapeutics, Inc.
    • Optimer Pharmaceuticals, Inc.
    • Trius Therapeutics, Inc.)
    • Idenix Pharmaceuticals, Inc.
    • Immune Design Corporation
    • Inspire Pharmaceuticals, Inc.
    • IOmet Pharma
    • iOnctura SA
    • Integrated Therapeutics Group
    • Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd.
    • MSD K.K. (Japan)
    • Nobilon International BV
    • Novacardia
    • OncoEthix SA
    • Organon BioSciences
    • Peloton Therapeutics, Inc.
    • Pandion Therapeutics, Inc.
    • Rigontec GmbH
    • Schering-Plough Corporation
    • SmartCells, Inc.
    • Tilos Therapeutics, Inc.
    • Vallee S.A.
    • Viralytics Limited (ASX:VLA)
    • Themis Biosciences GmbH
UsernamePublicRestriction

Register